tbuckley/cabot-search huggingface dataset:
Consanguineous Marriage
Authors: A. T. Sandison
Journal: BMJ (1964)

certain peculiar features which suggest that all these remains belong to one family-or to several families united by common -descent."'" Thus three of six crania possess large and uncommon Wormian bones."2Professor Stuart Pigott says this about the bones from Lanhill Long Barrow (Wilts): " It was possible to show that the nine individuals were members of one particular family group, recognizable not only by the striking similarities in features, but also in the presence of the rare Wormian ossicles in seven of the nine skulls."'Anatomists and radiologists, on the other hand, have not been categorical about the alleged familial incidence of Wormian bones.Indeed they appear to have shown little interest in the problem.-Iam, etc.,
Abstract 4546: Functional cell surface proteomics of acute myeloid leukemia enables predictive modeling of antibody-drug conjugate cytotoxicity
Authors: Robert Lawrence, Robert Thurman, Travis Biechele, Cristina Tognon, Samantha Savage, Anna Reister Schultz, Jeffrey Tyner, William Arthur
Journal: Cancer Research (2019)

Abstract Acute myeloid leukemia (AML) remains a significant unmet medical need. The development of targeted therapies for AML is challenging due to the heterogeneity of immunological and genetic disease subtypes and physiological similarities shared by blasts and normal myeloid progenitor cells. The identification of abundant cell surface markers on AML blasts with limited expression on bone marrow progenitors could drive the development of novel antibody-drug conjugates (ADCs) and other antibody-based therapeutics with improved therapeutic windows. Here we used hydrazide chemistry and mass spectrometry-based proteomics to profile the cell surface landscape of 95 primary blast samples from the Beat AML research consortium and normal bone marrow progenitor cells from healthy donors. We measured the abundance of over 5,000 proteins with high reproducibility (R2 = 0.89) and coverage of known cell surface markers (240/371). We also identified more than 2,500 N-glycosylation sites, many of which are predicted by canonical sequence motifs but have not been demonstrated experimentally. These findings thereby expand our knowledge of both the AML and normal hematological cell surface proteome. Additionally, we used pulsed stable isotope labeling coupled with the aforementioned hydrazide method to assess global surface protein abundance and turnover dynamics in a panel of malignant cell lines. We integrated our cell surface characterization with Beat AML’s mRNA expression, mutation, and AML subtype classification data to prioritize proteins for further exploration as candidate targets for ADC therapeutics. We generated a library of ADCs using monoclonal antibodies conjugated with Auristatin T, a highly potent membrane impermeable microtubule inhibitor, and measured ADC cytotoxic activity on a panel of AML cell lines as well as primary bone marrow progenitor cells. We used these integrated datasets to more precisely refine AML subtypes and identify patient populations that could benefit from novel AML ADCs. We report the preclinical validation of CD317 as a proof-of-concept for the utility of cell surface proteomics to identify novel targets for ADC therapeutics. Citation Format: Robert Lawrence, Robert Thurman, Travis Biechele, Cristina Tognon, Samantha Savage, Anna Reister Schultz, Jeffrey Tyner, William Arthur. Functional cell surface proteomics of acute myeloid leukemia enables predictive modeling of antibody-drug conjugate cytotoxicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4546.
Population-based outcome of stages IA-IIA resected gastric adenocarcinoma: Who should get adjuvant treatment?
Authors: Jason S. Gold, Riad H. Al Natour, Mandeep S. Saund, Charles H. Yoon, Ashish M. Sharma, Qin Huang, Valia A. Boosalis, Edward E. Whang
Journal: Journal of Clinical Oncology (2012)

75 Background: The benefit of adjuvant treatment in gastric adenocarcinoma was demonstrated by randomized controlled studies that predominantly enrolled patients with locally advanced tumors. Thus its role for stage IIB – IIIC disease is widely accepted. Our aim was to identify patients with stage IA – IIA gastric adenocarcinoma who have a poor prognosis and therefore may benefit from adjuvant treatment. Methods: Patients with local or local-regional gastric adenocarcinoma who underwent surgical resection with pathological evaluation of ≥15 lymph nodes and had available disease-specific survival (DSS) data were identified from the Surveillance Epidemiology and End Results Registry. AJCC 7 th edition gastric cancer staging was used. Kaplan-Meier survival was estimated. Survival differences were evaluated with the logrank test and Cox multivariate analysis. Results: TN grouping strongly predicted DSS (p&lt;0.001, n=8515 patients). Stage IA (T1N0) (n=887) tumors had a distinctly excellent outcome, 91±1.2% DSS at 5 years, and thus were excluded from further analysis. The 5 TN groups of stages IB and IIA (n=1544) had the next best outcomes with DSS ranging from 66±4.6% to 81±2.3% at 5 years. Older age (p&lt;0.001), higher grade (p=0.004), larger size (p&lt;0.001), and proximal tumor location (p&lt;0.001) were independent predictors of worse DSS in stage IB and IIA tumors. Interestingly, T and N stages did not independently predict outcome (p=0.07, p=0.41 respectively). We devised a risk stratification scheme for stage IB and IIA tumors where 1 point was assigned for each of the following variables: age &gt;60 years, tumor size &gt;5 cm, proximal tumor location, and grade other than well differentiated. DSS was 100% at 5 years for patients with no points (n=2); 86±4.3% for those with 1 point (n=92); 76±3.0%, 2 points (n=325); 72±2.8%, 3 points (n=372); and 48±4.9%, 4 points (n=136) (p&lt;0.001). Conclusions: Patients with stage IB and IIA gastric adenocarcinomas with at least 2 adverse features (age &gt;60 years, tumor size &gt;5 cm, proximal tumor location, and grade other than well differentiated) have 5 year DSS ≤76%. Adjuvant therapy may be warranted for these patients.
Die kretinische Entartung nach anthropologischer Methode.
Authors: Nach Anthropologischer, Methode Bearbeitet, Von Ernst, Einem Arzt Mit, D Geleitwort, Wegelin Karl, Des Direktor, Instituts Pathologischen, Universitat D&r
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DISINFECTANTS.
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OC-063 Introduction of An Inflammatory Bowel Disease Nurse Flexible Sigmoidoscopy Clinic Improves Patient Care by Initiating Earlier Treatment and Saves Clinic Slots
Authors: HE Johnson, SA Weaver, SD McLaughlin
Journal: Gut (2016)

<h3>Introduction</h3> It is a marker of quality to be able to respond promptly and effectively to a patient with inflammatory bowel disease (IBD) at a time of flare. Many patients who contact the IBD helpline with flare symptoms require a flexible sigmoidoscopy (FS) for accurate assessment. These are usually performed on generic lists where follow up to consider a new treatment plan is arranged resulting in delays in treatment and creating pressure on clinic slots. An experienced IBD nurse prescriber (IBDN) was trained in FS with the aim to endoscopically assess patients and potentially start new treatment the same day. <h3>Aim</h3> Report the outcomes from the first 2 years of the IBD nurse endoscopist clinic <h3>Methods</h3> Records were reviewed of all patients attending the IBDN FS clinic. We evaluated the time from referral to FS, diagnoses, demographics and outcomes. <h3>Results</h3> 410 patients underwwent a FS with the IBDN 195 (47.6%) patients referred for rectal bleeding did not have IBD. 215 (52.4%) had a known diagnosis of IBD, 152 (70.7%) ulcerative colitis and 63 (29.35%) Crohn’s disease. 130 (60.5%) were female, mean age: 48 (range 16 – 88). Referral origin: 76 (35.3%) IBD Helpline. 58 (27%) IBD Consultant clinic. 39 (18.1%) IBDN Clinic. 27 (12.6%) Other medical clinic. 11 (5.1%) inpatient. 4 (1.9%) primary care. FS outcome: 55 (25.6%) commenced azathioprine, 47 (21.9%) started oral prednisolone, 38 (17.7%) commenced 5 ASA therapy, and 19 (8.8%) no changes to their care. In 41 (19.1%) FS was performed to assess need for or response to biological therapy. The 11 (5%) in-patients returned to the ward, 4 (1.9%) diagnosed with acute severe ulcerative colitis. Mean time from referral to test: 7 days, (range 0 – 28). In total 137 clinic slots were saved over 2 years, 76 direct from the helpline avoiding an urgent clinic slot. Following FS, 51 (23.7%) patients were discussed at the next IBD MDT, saving a follow up clinic slot. At the MDT the endoscopy findings were reviewed and discussed and appropriate treatment confirmed with the patient in the IBD telephone clinic. 10 (4.7%) patients were referred direct to the day unit to commence biological therapy following confirmation of active disease at FS as per the treatment plan from the Consultant referral. <h3>Conclusion</h3> The IBDN FS clinic reduced the time interval between developing symptoms and starting a new treatment plan in patients with IBD. The skilled prescribing IBD nurse endoscopist made changes in 91.2% at the time of the FS. The relatively small number of patients starting 5 ASA therapy suggests this had been optimised prior to FS suggesting patients attending the IBDN FS clinic had moderate to severe IBD. The introduction of the IBDN FS clinic also led to a reduction in demand on outpatient clinic slots. <h3>Disclosure of Interest</h3> H. Johnson: None Declared, S. Weaver: None Declared, S. McLaughlin Conflict with: Sponsored by Abbvie
The National Health Service reforms
Authors: M. F. Loudon
Journal: JAMA (1989)

<h3>'Safe in Our Hands'</h3> American physicians may not realize that most British specialists and general practitioners (GPs), and their patients, are very fond of the National Health Service (NHS) and regard it as a public property, separate from party politics. They feel this even though the NHS has a true socialist structure—a comprehensive health care industry that is state regulated, monopolistic, free to all consumers at the point of use, and funded from central taxation. Free marketers, however, object to such structures in principle, believing the structures to be an infringement of personal liberty, unresponsive to consumers' needs, and inherently inefficient. Under the current system, the Department of Health allocates (taxpayers') money to the 21 regional health authorities, which in turn fund their constituent district health authorities, which manage the hospitals. Specialists are salaried employees, work in hospital wards and outpatient departments, and are paid by their district health authority.
Ischemia of the hand secondary to levarterenol bitartrate extravasation. Methods of management
Authors: P. M. Weeks
Journal: JAMA (1966)

LEVARTERENOL (Levophed) bitartrate is a potent vasoconstrictor frequently used in the management of nonhemorrhagic shock. Ischemic necrosis of the skin secondary to extravasation of the drug is a frequent occurrence.<sup>1-4</sup>In the severely ill patient, a paucity of veins may necessitate use of the vessels on the dorsum of the hand for levarterenol infusion. This paper reports two cases of levarterenol extravasation into the dorsum of the hand resulting in complete venous occlusion of the hand and ischemic necrosis of the digits. Complete venous occlusion in these cases resulted from compression of the dorsal and volar venous systems by progressive edema beginning on the dorsum of the hand and spreading into the palmar spaces. A method for reversal of this occlusive process is presented. <h3>Report of Cases</h3><h3>Case 1.—</h3> This patient was administered levarterenol while undergoing evacuation of an epidural hematoma. The intravenous fluids infiltrated, and approximately 75 cc
ACUTE SINUSITIS.
Authors: J. A. STUCKY
Journal: JAMA (1903)

On account of the irregularity in shape and uncertainty of size, location and communication of the accessory cavities of the nose, the diagnosis of the exact cavity or sinus involved in the acute stage of inflammation is frequently impossible. In the subacute or suppurative stage the diagnosis is not often difficult. Time will not be taken to refer in detail to these irregularities. The recent original research and publications made by Cryer of Philadelphia, B. Douglas of New York and Turner of London, have added greatly to our knowledge of the minute anatomy, and to them we are indebted for knowledge that enables us to deal radically and successfully with these pathologic conditions. Attention is briefly called to the meati of the nasal cavities because the accessory sinuses communicate through them to the nasal chamber. These sinuses, or air chambers, both on anatomic and clinical grounds, are divided into two
Physician Travelers
Authors: Craig S. Hoyt
Journal: JAMA (1972)

<h3>To the Editor.—</h3> I enjoyed reading Dr. Meehan's article "Physician Travelers" (220:97, 1972). However, in her search into antiquity Dr. Meehan has overlooked an important, modern physician traveler, Dr. Clifford Graves. Dr. Graves, a retired surgeon living in La Jolla, Calif, is the president and inspirational source of the International Bicycle Touring Society. In the past 30 years, he has cycled in Europe, Asia, and North America, and he has written scores of fascinating recounts of his adventures. His personal example that the bicycle is a complete and uncompromised alternative to the exalted combustion engine is an achievement of more than rhetorical significance in our ecology-minded age. Readers of Dr. Graves' cycle exploits know that his travels rival any of those described by Drs. Bell, Holland, and others.
Economic Cost of Cancer Mortality Is High in U.S., Regardless of How Cost Is Measured
Authors: Robin Yabroff, Cathy Bradley
Journal: JNCI Journal of the National Cancer Institute (2008)

Is High in U.S., Regardless of How Cost Is MeasuredThe economic cost of death due to cancer is high in the United States, regardless of whether researchers estimate the economic impact in lost work productivity or in a more global measure using the value of one year of life, according to two studies published online December 9 in the Journal of the National Cancer Institute .Researchers can estimate the economic burden of cancer mortality in terms of lost years of work (the human capital approach) or using the willingness-to-pay approach, which calculates the impact based on how much people would pay to gain one additional year of life ($150,000 based on prior studies in the U.S.).To gain a more comprehensive understanding of the economic impact of cancer mortality,
Regulating the drugs industry transparently
Journal: BMJ (2005)

make precise conclusions about the size of the effect, though the consistency of the associations we observed between both infant size and growth and later obesity across a range of settings and time periods suggest that the association is robust.As this review was part of a much larger review it was impractical to obtain original data from study authors to carry out secondary analyses. ConclusionsInfants in the highest end of the distribution for weight or body mass index and those who grow rapidly are at increased risk of obesity in childhood and adulthood.This suggests that factors during infancy or before that are related to infant growth influence the risk of later obesity.The relation of infant growth with other health outcomes should be explored to assess whether interventions to alter infant growth to prevent obesity are likely to be associated with other benefits or harms.It will also be important to assess whether factors influencing infant growth are amenable to change, to establish which strategies might alter infant growth, and to find out whether these are acceptable to parents.
THE MODERN TREATMENT OF FRACTURES
Authors: B. Hunt
Journal: BMJ (1855)

l. ~~~~~7,, h.ml yet anothe mum .fr the geamm prlysis of the isane-on, located not in the menings, as Bayle teaches s, nor in the cortical substance of tie brain, as Calmeil a_srts, but 'm the medullary (fibrous) or white substance d thw cbral mass.This, he says, is indurated in all eas of mania, complicated with genral paralyi.ach ebral fibre has contracted morbid adhesions with the unounding fibres, so as to render their separation impos- uji."Such are his words.
Eighteen-month follow-up of gastric freezing in 173 patients with duodenal ulcer
Authors: C. R. Hitchcock
Journal: JAMA (1966)

Gastric freezing for chronic duodenal-ulcer disease has been performed in 173 cases and an 18-month minimum follow-up has been achieved. The overall study indicates that 92.5% of the patients had symptoms or corrective surgery for recurrent disease at the time of the 18-month evaluation. Patients experience relief from previously distressing symptoms immediately following gastric freezing but the secretion of hydrochloric acid quickly returns to prefreeze levels or higher. Some patients are deceptively asymptomatic at three months postfreeze although acid levels are again high. Gastric freezing is a dramatic episode in the life of a patient with chronic duodenal ulcer and it appears to have a rather strong emotional appeal and to support subjective relief even in the absence of objective improvement.
Transactions of the Medical Society of the State of California.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quality of care provided to prostate cancer patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy: Results of a chart audit.
Authors: Henriette Breunis, Rehab Chahin, Husayn Gulamhusein, Shabbir M.H. Alibhai
Journal: Journal of Clinical Oncology (2015)

e16074 Background: Men with prostate cancer (PC) on androgen deprivation therapy (ADT) are at risk of osteoporosis and fragility fractures. Comprehensive evaluation and management of bone health in these men can prevent fragility fractures and improve quality of life and survival. Multiple studies show gaps in the quality of bone health care for these men in terms of timely screening, prevention, and treatment strategies. Clinicians treating patients on ADT increasingly recognize these care gaps and are referring patients on ADT to specialized osteoporosis clinics for assessment and management but the quality of care provided in these clinics has not been reported or whether such care was concordant with guidelines. Methods: Charts for 100 consecutive men (mean age 73.0 y) on ADT referred to a tertiary osteoporosis clinic in Toronto, Canada, between 2010 and 2014, were reviewed. The quality of care issues that were examined include bone health services provided, use of national guidelines, and fracture risk assessment tools for targeting appropriate therapy. Results: The median duration of ADT was 1.76 yrs (IQR 0.79-3) at the baseline visit. 20 patients had their first bone mineral density test before starting ADT and 33 during the first year of use. At initial consultation, 51 and 37 patients were taking inadequate amounts of calcium and vitamin D, respectively. A validated fracture risk assessment tool was used in all patients; 42 had a moderate 10-year fracture risk and 12 were high risk. 16 (72.7%) of sedentary patients were advised to increase physical activity. 68 (95.8%) and 32 (86.5%) of patients not taking appropriate amounts of calcium and vitamin D, respectively, were recommended to adjust intake to guideline levels. All patients at high fracture risk were recommended a bisphosphonate. Conclusions: The majority of referred patients had moderate to high fracture risk. The Osteoporosis clinic recommended guideline-based bone health care for most of these men. Since the risk of bone loss is highest in the first year of starting ADT early referral of PC patients on ADT to an Osteoporosis clinic will optimize bone health care.